Failure of crizotinib based systemic treatment in ALK positive histiocytosis involving the central nervous system: a case report and literature review

Table 1 Clinical characteristics of ALK-positive histiocytosis in the literature

No	Age	Sex	Position	Ethnicity	Localized or Disseminated	Surgery	Base mutation	Chemotherapy	Follow-up
1 [2]	15 years,	M	Cavernous sinus	Caucasian	Localized	No	KIF5B-ALK	ALK-inhibitor	No recurrence after 6 months
2 [3]	7 years,	F	Cerebellum	NA	Localized	Total resection	KIF5B-ALK	No	No recurrence after 12 months
3 [3]	10 years,	F	Cerebrum	NA	Localized	Total resection	KIF5B-ALK	No	No recurrence after 6 months
4 [14]	11 years	F	Right frontal lobe	NA	Disseminated	Total resection	KIF5B-ALK	No	No recurrence after 4 months
5 [14]	10 months	M	CNS, pulmonary, hepatic and peritoneal nodule	NA	Disseminated	Partial resection	KIF5B-ALK	ALK-inhibitor	Stable at 7 months
6 [12]	51 years	F	Lung, CNS	Asian	Disseminated	Tumor resection	KIF5B-ALK	ALK-inhibitor	Stable at 7 months
7 [2]	2 years, 9 months	M	Intestine, bone marrow, CNS	Middle Eastern	Disseminated	No	NA	etoposide, cyclosporine, immunoglobulins, cytarabin, methotrexate	Died after 2 months
8 [7]	49 years	M	CNS, bone, soft tissue, visceral organs, pleura	Caucasian	Disseminated	No	KIF5B-ALK	Gamma knife, lenalidomide, pembrolizumab, ALK inhibitor	Stable at 7 months
9^a	1 year, 4 months	M	Suprasellar	Chinese	Disseminated	Partial resection	KIF5B-ALK	ALK-inhibitor + cytarabine + vincristine	Six months

ISSN: 1471-2431